Last reviewed · How we verify
seasonal split influenza vaccine
Sinovac Biotech's seasonal split influenza vaccine is currently marketed, positioning the company as a player in the annual flu vaccine market. The key composition patent is set to expire in 2028, providing a period of exclusivity that supports the vaccine's competitive edge. The primary risk lies in the potential increase in competition following the patent expiry, which could impact market share and revenue.
At a glance
| Generic name | seasonal split influenza vaccine |
|---|---|
| Sponsor | Sinovac Biotech Co., Ltd |
| Modality | Biologic |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Phase 3 Study to Evaluate the Immunogenicity and Safety of Inactived Split Influenza Vaccine in Healthy Korea Infants (PHASE3)
- Immunogenicity and Safety Study of an Inactivated Influenza Vaccine (Split Virus, Vero Cell Derived) in Adults Aged 50 Years and Older (PHASE3)
- Immunogenicity Study of an Inactivated Influenza Vaccine (Split Virus, Vero Cell Derived) to Prevent Culture Confirmed Influenza Infection (PHASE3)
- A Study to Evaluate the Safety and Immunogenicity of a Single Dose of H1ssF-3928 mRNA-LNP in Healthy Adults (PHASE1)
- Inactivated Split Virus Seasonal Influenza Vaccine (Vero Cell-Derived) (PHASE3)
- A Study of An Adjuvanted Inactivated H7N9 Influenza Vaccine (PHASE2)
- Safety and Immunogenicity of GPO Seasonal Tetravalent Inactivated Split Virion Influenza Vaccine in Healthy Thais (PHASE1, PHASE2)
- Study of Biomarkers of Immune Activation Associated with Symptoms and Immune Responses After Influenza Vaccination in Adults (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |